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Abstract
The underlying pathophysiology of type 1 diabetes involves autoimmune-mediated islet
inflammation, leading to dysfunction and death of insulin-secreting islet β cells. Recent studies
have shown that polyamines, which are essential for mRNA translation, cellular replication, and
the formation of the hypusine modification of eIF5A may play an important role in the progression
of cellular inflammation. To test a role for polyamines in type 1 diabetes pathogenesis, we
administered the ornithine decarboxylase inhibitor difluoromethylornithine to 2 mouse models—
the low dose streptozotocin model and the NOD model—to deplete intracellular polyamines, and
administered streptozotocin to third model, which was haploinsufficient for the gene encoding the
hypusination enzyme deoxyhypusine synthase. Subsequent development of diabetes and/or
glucose intolerance was monitored. In the low dose streptozotocin mouse model, continuous
difluoromethylornithine administration dose-dependently reduced the incidence of hyperglycemia
and led to the preservation of β cell area, whereas in the NOD mouse model of autoimmune
diabetes difluoromethylornithine reduced diabetes incidence by 50%, preserved β cell area and
insulin secretion, led to reductions in both islet inflammation and potentially diabetogenic Th17
cells in pancreatic lymph nodes. Difluoromethylornithine treatment reduced hypusinated eIF5A
levels in both immune cells and islets. Animals haploinsufficient for the gene encoding
deoxyhypusine synthase were partially protected from hyperglycemia induced by streptozotocin.
Collectively, these studies suggest that interventions that interfere with polyamine biosynthesis
and/or eIF5A hypusination may represent viable approaches in the treatment of diabetes.
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INTRODUCTION
Type 1 diabetes (T1D) is a disorder of glucose homeostasis that is characterized by an
autoimmune reaction against islet β cells, coupled with an enhanced susceptibility of β cells
to inflammatory dysfunction and death (Atkinson et al. 2011; Lehuen et al. 2010). In the
non-obese diabetic (NOD) mouse model, pathogenesis of T1D begins early in life when the
release of β cell antigens—possibly a result of normal neonatal β cell turnover—leads to
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accumulation and activation of antigen-presenting cells in the islet (Mathis et al. 2001).
Subsequent presentation of these antigens to naïve T cells in the draining pancreatic lymph
node leads to T cell differentiation and proliferation, whereby specific CD4+ effector T cell
subtypes (most notably Th1, but possibly also Th17 cells) promote eventual β cell
destruction. Regulatory T cells (Tregs) are thought to inhibit this process, and recent studies
suggest that the balance between the effector T cells and Tregs may determine the overall
susceptibility to β cell destruction (Cabrera et al. 2012). More recently, it has been suggested
that the β cell itself may be an independent determinant in the progression of its own demise,
such that specific genes or pathways in the β cell itself confer susceptibility or resistance to
either initial antigen release or subsequent immune-mediated death (Atkinson et al. 2011;
O'Sullivan-Murphy and Urano 2012). Whereas the mainstay of treatment for T1D is insulin
replacement, several clinical trials have examined the potential for therapeutics that
modulate immune tolerance or block the pathway beginning from antigen presentation to T
cell differentiation and proliferation (Matthews et al. 2010). Although some of these clinical
trials have shown initial preservation of insulin secretion (and, by inference, β cell mass and
function) in new-onset diabetic subjects, none has resulted in durable preservation of insulin
secretion or reversal of the disease process itself. Thus, there is an unmet need for the
identification of new treatments that may impact T1D pathogenesis.
The native polyamines (putrescine, spermidine, and spermine) are polycationic aliphatic
amines that influence nucleic acid structure and stability, modulate ion channel activity,
govern mRNA translation rates, and are required for formation of the activating “hypusine”
modification of the pro-inflammatory translational factor eIF5A (Igarashi and Kashiwagi
2010). Given their functions, alterations in polyamine accumulation might be expected to
influence multiple aspects of T1D pathogenesis, including the production of autoantigens or
formation of “neoantigens” in β cells, expression of costimulatory molecules, differentiation
or proliferation of T cell subtypes, and the β cell inflammatory response (Brooks 2012).
Polyamine accumulation in cells is controlled by three major processes: endogenous
production, cellular uptake, and degradation. Production of polyamines is governed in part
by the activity of the enzyme ornithine decarboxylase (ODC), which converts ornithine to
putrescine (Igarashi and Kashiwagi 2010). Inhibition of ODC using the ornithine analog
difluoromethylornithine (DFMO) has proved an attractive approach for depleting cellular
polyamines in cells and in animals, and is clinically approved for use in humans. Although
studies have shown that DFMO potently depletes putrescine and spermidine levels in islet β
cells (Sjöholm et al. 1993), no study has directly addressed the effect of this reduction on the
outcome of T1D in mouse models. As a prelude to potential studies in humans, here we
undertook a study in three different mouse models of T1D to address the effect of polyamine
depletion (by DFMO) and deoxyhypusine synthase (DHS) deficiency on diabetes
development. Our results show that DFMO feeding of animals results in a dose-dependent
decrease in T1D incidence and partial protection against diabetes under conditions of DHS
deficiency. Our data suggest that the protective effects of polyamine depletion may be in
part related to reductions in eIF5A hypusination.
MATERIALS AND METHODS
Animals and procedures
All procedures relating to mice were approved by the Indiana University Institutional
Animal Care and Use Committee. 8 week old male C57BL/6J and 5 week old female NOD
mice were purchased from Jackson Laboratories (Bar Harbor, ME). The generation of mice
heterozygous for deletion of the gene encoding DHS (Dhps) was described previously
(Templin et al. 2011). Dhps+/− mice were maintained on a mixed C57BL6/129SvEv
genetic background. Intraperitoneal glucose tolerance tests (GTTs) using 2 g/kg body weight
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glucose were performed as previously described (Evans-Molina et al. 2009). Islets and
splenocytes were isolated also as described previously (Cabrera et al. 2013; Stull et al.
2012).
Diabetes Induction and DFMO treatment
For the multiple low dose streptozotocin (STZ) experiments, 8 week-old C57BL/6J mice
were begun on difluoromethylornithine (DFMO, a gift from Dr. P. Woster) treatment at 0,
0.25, or 0.5 wt% added directly in the drinking water 3 days prior to STZ treatment, and
then maintained on the respective dose of DFMO for the remainder of the study. STZ was
administered intraperitoneally at a dose of 55 mg/kg body weight for 5 consecutive days as
described previously (Maier et al. 2010). STZ experiments in Dhps+/− mice were
performed similarly, except that mice did not receive DFMO. Blood glucose was monitored
twice weekly using a hand-held glucometer and a GTT was performed at the end of the
study (4 weeks following the start of DFMO treatment) (Evans-Molina et al. 2009).
For T1D prevention studies, female NOD mice were treated continuously with 0, 0.25, or
1.0 weight percent (wt%) DFMO in drinking water between 6 and 10 weeks of age. No
differences in water intake between control and DFMO-treated animals were observed.
Blood glucose was monitored weekly using a hand-held glucometer and diabetes was
diagnosed when two consecutive blood glucose values exceeded 250 mg/dL.
Immunoblots, immunohistochemistry, β cell area, and insulitis scoring
Immunoblots from islet and splenocytes extracts were performed as described previously
(Maier et al. 2010) using antibodies against eIF5A (BD Biosciences) and hypusinated
eIF5A, and image quantifications were performed using Li-Cor software (Li-Cor
Biosciences, Lincoln, NE). For immunohistochemistry experiments, pancreata from mice
were fixed, sectioned and stained for insulin as described (Evans-Molina et al. 2009).
Images were acquired using a Zeiss AxioObserver Z1 equipped with a high-resolution color
camera (Carl Zeiss, Thornwood, NY). Islet β cell area was calculated as described
previously (Maier et al. 2010) using 3 sections per pancreas (75 μm apart) from at least 3
mice per group. For insulitis scoring, 3 pancreas sections at least 75 μm apart from 5
animals per group were graded by 2 independent observers (one of whom was blinded to
sample identity) using the following scheme: grade 1: no islet-associated mononuclear cell
infiltrates; grade 2: peri-insulitis affecting less than 50% of the circumference of the islet
without evidence of islet invasion; grade 3: peri-insulitis affecting greater than 50% of the
circumference of the islet without evidence of islet invasion; grade 4: islet invasion.
Flow cytometric analysis
At the time of diabetes diagnosis or when mice aged to 24 weeks (whichever occurred first),
single cell suspensions of pancreatic lymph node cells were prepared for flow cytometry as
described (Cabrera et al. 2013). For analysis of Treg cell populations, equal volumes of the
single cell suspensions were stained using anti-CD4 (clone RM4–5) and anti-CD25
(PC61.5) antibodies and fixed overnight before being permeabilized and stained with anti-
Foxp3 (FJK-16s) antibody according to the manufacturer's instructions (eBioscience, San
Diego, CA). For analysis of Th1 and Th17 cell populations, equal volumes of the single cell
suspensions were first incubated with 1X Cell Stimulation Cocktail (eBioscience) for four
hours prior to staining with anti-CD4 antibody; cells were fixed overnight then
permeabilized and stained for IL-17A (eBio17B7) and IFNγ (XMG1.2) according to
manufacturer's instructions (eBioscience). Cells were analyzed using a FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA) and FlowJo software (TreeStar, Ashland, OR).
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Serum measurements
Serum insulin levels were measured using the Ultra Sensitive Mouse Insulin ELISA kit
(Crystal Chem, Downers Grove, IL). The unmethylation index was determined using a
modification of a PCR-based assay described previously (Husseiny et al. 2012).
Statistical Analysis
All data are presented as the mean ± SEM. One-way ANOVA (with Bonferroni post-test)
was used for comparisons involving more than two conditions, and a two-tailed Student t
test was used for comparisons involving two conditions. Prism 5 software (GraphPad, La
Jolla, CA) was used for all statistical analyses. Statistical significance was assumed at
P<0.05.
RESULTS
Polyamine depletion protects against diabetes development in the low dose STZ model
To determine the effect of polyamine depletion on the development of diabetes in mice, we
employed a multiple low-dose STZ model (55 mg/kg body weight STZ x 5 days) of
inflammatory T1D, in which animals develop a T1D-like phenotype with local islet
inflammation and resultant hyperglycemia over time (Calderon et al. 2008; Lukic et al.
1998). Male C57BL/6J mice that were fed DFMO were compared to control animals in this
STZ model. No differences were observed in water consumption between control and
DFMO-fed mice (data not shown). As shown in Fig. 1A, mice fed 0.5 wt% DFMO exhibited
a substantially reduced incidence of diabetes (defined as random blood glucoses >250 mg/dl
on two consecutive measurements), with 80% of animals remaining diabetes-free at the end
of the study. By contrast, 0–10% of control animals and those fed 0.25 wt% DFMO
remained diabetes-free at the end of the study. We also examined the severity of
hyperglycemia, as shown in Fig. 1B. Whereas blood glucoses of untreated and STZ-treated
mice diverged by day 17 after initiation of the experiments, mice fed 0.5 wt% DFMO in the
drinking water concurrent with STZ treatment remained normoglycemic throughout the
course of the study. Mice fed a lower dose of 0.25 wt% DFMO displayed a less severe
hyperglycemic phenotype (Fig. 1B), suggesting a dose-dependent effect of DFMO on
diabetes development in this model. Likewise, STZ-treated control mice had significantly
worsened glucose tolerance as assessed by GTT at 4 weeks post STZ, whereas 0.5 wt%
DFMO-fed mice displayed glucose tolerance indistinguishable from non-STZ treated
controls, and 0.25% DFMO-fed mice showed an intermediate tolerance (Fig. 1C and D).
Whereas control mice and mice fed 0.25 wt% DFMO exhibited significantly reduced β cell
area percentages in their pancreas relative to non-STZ-treated mice, mice fed 0.5 wt%
DFMO showed statistically indistinguishable β cell area percentage compared to non-STZ-
treated mice (Fig. 1E). Analysis of paraffin-embedded pancreatic sections also showed
substantially greater insulin staining in 0.5 wt% DFMO-fed mice compared to STZ-treated
control mice (Fig. 1F). Collectively, the data in Fig. 1 suggest that polyamine depletion
using DFMO protects islet β cells from inflammation-induced dysfunction and destruction.
Polyamine depletion delays the onset of T1D in NOD mice
To test the effects of polyamine depletion in an autoimmune mouse model of T1D, we
conducted DFMO feeding studies in female non-obese diabetic (NOD) mice. Female NOD
mice develop insulitis as early as 4 weeks of age and display increasing islet endoplasmic
reticulum (ER) stress, inflammation, and β cell dysfunction until 10–12 weeks of age, after
which β cell mass declines and diabetes ensues (Sherry et al. 2006; Tersey et al. 2012). As
shown in Fig. 2A, >90% of female NOD mice developed diabetes between 13–25 weeks of
age in our vivarium. Based on the studies in Fig. 1, we hypothesized that depletion of
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polyamines during the inflammatory/ER stress phase of the disease (between 6 and 10
weeks of age in NOD mice) would reduce islet β cell stress and subsequently delay or
prevent T1D. As shown in Fig. 2A, whereas NOD mice that were fed 0.25 wt% DFMO
between 6 and 10 weeks of age showed a similar rate of diabetes incidence as control mice,
mice treated with 1.0 wt% DFMO showed a 50% decrease in the incidence of diabetes.
Serum insulin levels measured at the time of euthanasia (regardless of whether animals had
diabetes or not) were significantly higher in mice fed 1.0 wt% DFMO compared to either
controls or mice fed 0.25 wt% DFMO (Fig. 2B). Consistent with these increased serum
insulin levels, the relative β cell area in pancreata of 1.0 wt% DFMO-fed mice was 10-fold
higher than control mice (Fig. 2C). Consistent with the observation of greater β cell area,
mice fed 1.0 wt% DFMO exhibited a significantly reduced index of unmethylated
preproinsulin in the serum (a biomarker that directly correlates with β cell death (Akirav et
al. 2011; Husseiny et al. 2012), suggesting lower β cell death in these animals (Fig. 2D).
Polyamine depletion in NOD mice correlated with reduced insulitis, increased pancreatic
lymph node Treg cells, and reduced pancreatic lymph node Th17 cells
NOD mice were next evaluated for insulitis by examining tissue sections from DFMO-fed
and control animals. To quantitate insulitis, we performed morphometric scoring of pancreas
sections, with higher scores reflecting greater insulitis (Cabrera et al. 2013). As shown in
Fig. 2E, 1.0 wt% DFMO-treated NOD animals had a significantly lower insulitis score at the
time of euthanasia compared to control animals.Fig. 2F shows representative images of
islets from fixed pancreas sections, with 1.0 wt% DFMO-fed mice showing less insulitis
compared to controls. DFMO-fed NOD mice had islets with either mild insulitis and robust
insulin staining (Fig. 2F, middle panel) or a significant amount of infiltrate while retaining
robust insulin staining (Fig. 2F, right panel), suggesting that DFMO may reduce or change
the makeup of infiltrate that surrounds the islet.
Whereas the reduction in overall insulitis in DFMO-fed animals may be a sufficient
explanation for the delay in diabetes development in these animals, it is also possible that
the composition of the cell types that make up the insulitis might also provide important
information. Because immune cells in insulitis are thought to arise from local pancreatic
lymph nodes (Mathis et al. 2001), we examined CD4+ T cell subsets in pancreatic lymph
nodes by flow cytometry as an assessment of T cell populations appearing in insulitis. Fig.
3A and 3B show gating strategies that were used to identify appropriate CD4+ T cells. As
shown in Fig. 3C, no differences were observed in total CD4+ T cells compared to total cells
in the pancreatic lymph nodes. There were also no differences in Th1 cells (as a percentage
of total CD4+ T cells) were observed in the pancreatic lymph nodes of 1.0 wt% DFMO-fed
mice compared to lymph nodes of control mice (Fig. 3D). Notably, however, pancreatic
lymph nodes of 1.0 wt% DFMO-fed NOD mice exhibited significantly increased immune-
tolerogenic Treg cells (as a percentage of total CD4+ T cells) compared to controls (Fig.
3E). Potentially pathogenic Th17 cells were reduced in the pancreatic lymph nodes of 1.0 wt
% DFMO-fed mice compared to controls (Fig. 3F).
DFMO treatment reduces hypusination of eIF5A in splenocytes and islets
Polyamine depletion might be expected to reduce hypusinated eIF5A (eIF5A-Hyp) via the
reduction in intracellular spermidine content. To determine if DFMO reduces eIF5A-Hyp in
immune cells, splenocytes from C57BL/6J mice were stimulated in vitro with anti-CD3,
anti-CD28, and IL-2 (with and without 50 μM DFMO) to mimic the nature of T cell
activation occurring in T1D (Tang et al. 2004). As shown in Fig. 4A, activated splenocytes
showed an increase in total eIF5A levels as well as an increase in eIF5A-Hyp levels (as
judged by the eIF5A-Hyp/total eIF5A ratio), consistent with prior observations that
activation of immune cell populations correlates with increases in hypusination rates (Kruse
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et al. 2000). Concurrent DFMO treatment substantially blunted the increase in eIF5A-Hyp
levels upon stimulation (Fig. 4A). One possible interpretation of these results could be that
reduced eIF5A hypusination consequent to DFMO treatment causes a reduction in insulitis
observed in our NOD experiments.
Hypusination of eIF5A has been shown to promote cytokine-induced inflammatory
responses in pancreatic islets (Maier et al. 2010; Nishiki et al. 2013). To determine if DFMO
feeding to mice reduces levels of eIF5A-Hyp in islets, we fed C57BL/6J mice ad lib for 3
days with 0, 0.25 or 1.0 wt% DFMO in the drinking water, and subsequently isolated their
islets. As shown in Fig. 4B, 1.0 wt% DFMO feeding reduced islet eIF5A-Hyp levels relative
to actin by almost 2-fold, accompanied by slight reductions in total eIF5A levels. 0.25 wt%
DFMO feeding resulted in a roughly 30%reduction in levels of eIF5A-Hyp relative to actin.
These data suggest that one benefit of polyamine depletion in our NOD experiments might
accrue from the reduction in inflammation-promoting eIF5A-Hyp.
Dhps heterozygosity protects against multiple low-dose STZ-induced diabetes
The data in Fig. 4A and B suggest that polyamine depletion overall might protect NOD mice
against T1D development via the reduction in eIF5A-Hyp levels. To test this possibility, we
subjected mice heterozygous for a targeted deletion of the gene encoding DHS (Dhps+/−
mice) to multiple low-dose STZ and followed animals for the development of
hyperglycemia. In prior studies, we showed that Dhps−/− mice are embryonic lethal and
Dhps+/− mice exhibited approximately 50% reduced rates of eIF5A hypusination (Templin
et al. 2011). As shown in Fig. 5A, islets from Dhps+/− mice exhibited reduced levels of
DHS protein by immunoblot. As shown in Fig. 5B, Dhps+/− mice began exhibiting
significantly improved blood glucose levels compared to wild-type littermates 12 days
following STZ injections, although complete protection against hyperglycemia as observed
in the 1.0 wt% DFMO-fed mice did not occur in the Dhps+/− mice. Dhps+/− mice exhibited
a tendency to increased β cell area compared to wild-type littermates (Fig. 5B), although this
difference did not reach statistical significance.
DISCUSSION
T1D is an autoimmune disease that is characterized in both mice and humans by a prodrome
that includes β cell dysfunction and dysglycemia (Ferrannini et al. 2010; Ize-Ludlow et al.
2011; Tersey et al. 2012). Both the immune activation cascade and inflammation-stressed
islet β cells are prominent targets for experimental therapies for T1D. However, such
therapies to date have proved inadequate to fully remit the disease (Matthews et al. 2010),
there is a need for identification of new molecular pathways that would serve as targets for
future therapies. Polyamines are polycationic aliphatic amines that have been implicated in a
variety of cellular functions that may directly impact inflammatory responses, including
stabilization of nucleic acids during transcription and replication, promoting mRNA
translation in response to inflammation, and alteration of cellular ion channel activity (for a
review, see ref. (Brooks 2012)). In this study, we examined the potential of targeting ODC, a
key enzyme in the polyamine biosynthetic pathway, with the aim to mitigate disease
incidence in T1D in two different mouse models: the multiple low-dose STZ model and the
NOD model. We show that treatment with the ODC inhibitor DFMO results in increases in β
cell area and insulin secretion, with improved blood glucose control and reductions in the
incidence of T1D. Our studies raise the possibility that targeting the polyamine biosynthesis
through small molecule inhibitors could favorably alter the course of T1D.
The multiple low-dose STZ model is often used to mimic inflammatory responses seen in
T1D. STZ is a DNA alkylating agent that is taken up selectively by β cells through
membrane GLUT2 transporters and leads to the formation of superoxide radicals and the
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liberation of toxic amounts of nitric oxide (Szkudelski 2001). In the low-dose STZ mouse
model, STZ is thought to cause low-level β cell death, which leads to the influx of
macrophages/dendritic cells that subsequently release inflammatory cytokines such as IL-1β
and TNF-α (Calderon et al. 2008; Maier et al. 2010). Pro-inflammatory cytokines lead to β
cell inflammation, dysfunction, and eventual apoptosis/necrosis (Steer et al. 2006). In this
study, we show that continual feeding of 1.0 wt% DFMO in the drinking water prevents
apparent β cell loss and the development of hyperglycemia in response to low-dose STZ. In
this respect, polyamine accumulation may contribute to cellular oxidative stress and
apoptosis when they undergo oxidative deamination by polyamine oxidase to generate H2O2
and aldehydes (acrolein) (Poulin et al. 1995; Seiler and Raul 2005); reduction of polyamine
levels by use of DFMO has been demonstrated in cell systems to protect against apoptotic
cell death (Bhattacharya et al. 2003; Ray et al. 2000). Indeed, among cells in the pancreas, β
cells have perhaps the highest intracellular polyamine levels, which are enhanced further
upon stimulation of cells with glucose (via stimulation of ODC activity) (Hougaard et al.
1986). Given that islet β cells also have strikingly low antioxidant capacity (Grankvist et al.
1981), it is tempting to speculate that sensitivity of β cells to oxidative destruction by STZ
could be enhanced by the presence of polyamines, and as such, depletion of polyamines
using DFMO allows for a greater capacity of β cells to resist the effects of STZ. Moreover,
oxidative stress is closely linked to ER stress (Scheuner and Kaufman 2008) and, as such,
reduction of oxidative stress may also reduce β cell ER stress.
Few studies have directly addressed a role for polyamines in the pathogenesis of
autoimmune T1D. Using a mouse model of autoimmune T1D, we show that 1.0 wt% DFMO
administration in the drinking water to mice between the age of 6 and 10 weeks resulted in
delayed incidence of T1D. Although we did not directly measure polyamine levels in islets
following DFMO, several previous studies have shown that DFMO administration to mice
results in tissue polyamine depletion (Sunkara and Rosenberger 1987; Thomas and Messner
1991). In prior studies, we showed that the period between 6 and 10 weeks of age in NOD
mice represents a time of increasing insulitis and β cell ER stress (Tersey et al. 2012). We
therefore hypothesized that administration of DFMO during this time period might have two
key effects that would lead to delayed incidence of T1D: (1) to reduce T cell proliferation/
differentiation, and/or (2) to reduce β cell ER and oxidative stress. With regard to the
former, prior studies have shown that depletion of polyamines using DFMO significantly
inhibited the T cell proliferative responses to a variety of known stimuli (concavalin A,
alloantigens) in vitro, and that this effect was reversed by supplementation with polyamines
(Singh et al. 1992). In agreement with this report, we demonstrate here that 1.0 wt% DFMO
administration leads to a reduction in insulitis in NOD mice. Moreover, we show that the
relative proportion of Tregs are increased and effector Th17 cells are reduced in pancreatic
lymph nodes of DFMO-fed NOD mice, a finding suggestive of an effect of polyamine
depletion that biases the differentiation of T cell subsets toward a more immune-tolerizing
balance. With respect to effects of polyamine depletion on β cell function, our studies show
that insulin secretion is significantly enhanced in NOD mice fed 1.0 wt% DFMO in the
drinking water. Although this effect might be secondary to the reduced insulitis in these
animals (and therefore reduced β cell inflammation), we cannot rule out an independent
effect of polyamine depletion on β cell function. Studies from the 1980s and 1990s
attempted to examine the effect of DFMO-induced polyamine depletion on β cell function
using primary rodent islets and rodent-derived β cell lines. DFMO was shown to diminish
putrescine and spermidine levels in these cells, but in some studies insulin release was
impaired (Sjöholm 1996; Welsh and Sjöholm 1988) and in others it was enhanced (Sjöholm
et al. 1993). Whereas differences might lie in the nature of cells used in these studies (cell
lines vs. primary islets), the implications with respect to whole animal glucose homeostasis
was not directly studied. Also, in none of these studies was the effect of polyamine depletion
studied with respect to the kind of ER or oxidative stress observed in NOD mouse islets,
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thereby leaving open the possibility that an effect of polyamines in β cells must be studied in
appropriate context.
Recent studies suggest that the more downstream effect of polyamines on eIF5A
hypusination may be particularly important. The enzyme DHS transfers the aminobutyl
moiety of spermidine to the ε-amino group of Lys50 of eIF5A, forming the hypusine residue
(Park et al. 2010). In the absence of hypusine formation (a result of either spermidine
depletion or DHS inhibition), the RNA binding and translational functions of eIF5A are
impaired. In antigen presenting cells, studies of Hauber and colleagues showed that
hypusine formation is required for the nucleocytoplasmic shuttling and translation of the
mRNA encoding the maturation marker CD83, without which antigen presenting cells are
impaired in their ability to activate T cells (Kruse et al. 2000). Recent data from our group
have shown that hypusine is also required in part for the production of the IL2 receptor α
chain (CD25) in murine T cells, without which T proliferation is impaired (unpublished
observations). Other recent studies by our group support a role for hypusine in facilitating
the β cell inflammatory response to pro-inflammatory cytokines, particularly with respect to
the translation of the mRNA encoding inducible nitric oxide synthase (Maier et al. 2010;
Nishiki et al. 2013). In this respect, we show that DFMO feeding to mice leads to a
reduction in hypusine formation in both activated splenocytes and islets. Furthermore, mice
heterozygous for the Dhps gene show resistance to low-dose STZ-induced diabetes in a
manner similar to DFMO feeding. These studies raise the intriguing possibility that the
effects observed with polyamine depletion in our studies may result from a reduction in
hypusine formation.
Taken together, our studies provide evidence that polyamine depletion might represent a
novel approach in the treatment of T1D. Although no studies to date have shown altered
levels of polyamines in individuals with T1D, the elevations in polyamine levels observed in
other autoimmune diseases such as lupus and rheumatoid arthritis suggest the possibility that
polyamines may be contributing to disease pathogenesis in autoimmune disorders (for a
review, see (Brooks 2012)). Nevertheless, an elevation in polyamine oxidase activity in the
sera of children with T1D compared to control subjects (Bjelakovic et al. 2010) suggests the
possibility that oxidative stress might be exacerbated in such individuals if polyamine levels
were to be elevated. The use of antioxidants in diabetes has proven variably efficacious in
mouse models (Haskins et al. 2003; Padgett et al. 2013), although to date no specific
therapies have been approved for use in humans. Our studies represent the first step toward
the elucidation of a role for polyamines in T1D and suggest a possible role for polyamine
depletion therapy as a means to control disease prevention or progression. Finally, it has
recently been suggested that the gut microbiome may contribute to triggering T1D in
susceptible individuals (Boerner and Sarvetnick 2011). Therefore, even in the absence of
elevated polyamine in diabetic individuals, it is possible that polyamine depletion may alter
the gut microbiome (Barry et al. 2011) and thereby provide some protection against diabetes
development. Future studies will include analysis of preclinical animal models in which
ornithine decarboxylase is mutated to ascertain the role of polyamines intrinsic to the
immune system and the β cell.
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Figure 1. Polyamine depletion protects against low-dose STZ-induced diabetes
Male C57BL/6J mice (N=10 per group) were fed DFMO in drinking water at the indicated
dose for 3 days prior to 5 daily intraperitoneal injections of STZ (55 mg/kg). (A) Survival
curve showing incidence of diabetes. Arrows indicate timing of STZ injections. (B) Weekly
blood glucose values. Arrows indicate timing of STZ injections. (C) GTTs at 30 days post
start of STZ injections. (D) Area under the curve corresponding to the GTTs in panel C. (E)
β cell area as a percent of pancreatic area in treated mice and controls. (F) Images of
representative pancreata immunostained for insulin (brown) and counterstained for
hematoxylin (blue). Scale bar = 200 μM. *P<0.05 compared to control (no DFMO).
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Figure 2. Polyamine depletion delays T1D incidence in female NOD mice
Female NOD mice (N=10 per group) were fed DFMO in the drinking water at the indicated
dose between 6 and 10 weeks of age. (A) Survival curve showing incidence of diabetes. (B)
Serum insulin concentration at diabetes occurrence or at 25 weeks of age, whichever
occurred first. (C) β cell area as a percentage of total pancreatic area. (D) Serum
unmethylation index (from N=5 mice per group). (E) Images of representative pancreata
immunostained for insulin (brown) and counterstained for hematoxylin (blue). Black arrows
indicate insulin immunostaining, red arrows indicate insulitis. Scale bar = 200 μM. (F)
Average insulitis score. *P< 0.05 compared to control (no DFMO).
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Figure 3. Polyamine depletion in NOD mice alters T cell population
Female NOD mice were fed DFMO in drinking water at the indicated dose between 6 and
10 weeks of age. At diabetes development or 25 weeks of age (whichever occurred first),
pancreatic lymph nodes from N=5 mice per group were harvested and flow cytometry was
performed. (A) Contour plots showing gating of CD4+ cells (upper panels), followed by
separation by CD25 and Foxp3 staining intensities (lower panels). (B) Contour plots
showing gating of CD4+ cells (upper panels), followed by separation by IFNγ and IL-17a
staining intensities (lower panels). (C) Percent of total CD4+ cells in pancreatic lymph node.
(D) CD4+IFNγ+ (Th1) cells as a percent of total CD4+ cells. (E) CD4+CD25+Foxp3+
(Treg) cells as a percent of total CD4+ cells. (F) CD4+IL17A+ (Th17) cells as a percentage
of total CD4+ cells. *P<0.05 compared to 0 wt% control.
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Figure 4. Polyamine depletion with DFMO reduces eIF5A-Hyp formation
(A) Splenocytes from C57BL/6J mice were stimulated in vitro with anti-CD3, anti-CD28,
and IL-2 (with and without 50 µM DFMO) and total protein was subjected to
immunoblotting for eIF5A and eIF5A-Hyp. (B) Total protein from islets from mice treated
for 3 days with 0, 0.25 or 1.0 wt% DFMO was subjected to immunoblotting for eIF5A and
eIF5A-Hyp. Quantified band intensity ratios as indicated are shown below each panel.
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Figure 5. Dhps heterozygosity protects against low-dose STZ-induced diabetes
8 week-old Dhps+/− male mice and wild-type littermates (N=5–10 per group) were treated
with 5 daily intraperitoneal injections of STZ (55 mg/kg, IP). (A) Islet extracts
immunoblotted for DHS and total eIF5A protein. (B) Weekly blood glucose values. Arrows
indicate timing of STZ injections. (C) β cell area as a percentage of total pancreatic area.
*P<0.05 compared to wild-type control.
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